Emalex

Emalex Biosciences

Chicago, United States · Founded 2018 · $285.0M raised

Headquarters
Chicago, Illinois
Employees
11–50
Founded
2018
Business Model
B2B
Total Funding
$285.0M
Last Round
$250.0M Series DNov 2022
Rounds
4

About

Emalex Biosciences is a Chicago-based clinical-stage biopharmaceutical company created by Paragon Biosciences in 2018. The company develops novel treatments for central nervous system disorders, with its lead asset ecopipam — a first-in-class selective dopamine D1 receptor antagonist — in late-stage development for pediatric Tourette syndrome. In April 2026, Teva announced its acquisition of Emalex for $700 million.

Summary

Emalex is a Biotech company based in Chicago, United States, founded in 2018. It has raised $285.0M in total across 4 rounds, most recently a $250.0M Series D round in Nov 2022. Investors include Paragon Biosciences, Bain Capital Life Sciences and Valor Equity Partners.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series DSeries DNov 2022
$250.0M

Sign up to see all 4 rounds

Series A through Series D — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Emalex on Indexed.vc
<a href="https://indexed.vc/companies/emalex"><img src="https://indexed.vc/api/badge/company/emalex" alt="Emalex on Indexed.vc" width="260" height="76" /></a>